Affordability

What to Do When Your Insurance Stops Covering Ozempic

7 min read · Published 04-30-2026 · Sources cited to FDA / NIH / clinical trials

When your insurance stops covering Ozempic, you have several concrete options: appeal the decision, use a manufacturer savings card, switch to a covered alternative, or explore compounded semaglutide. The right path depends on why coverage stopped and whether you're taking Ozempic for type 2 diabetes or weight loss.

Why Does Insurance Stop Covering Ozempic?

Coverage can end for several distinct reasons, and identifying yours determines your next move:

  • Formulary change: Your insurer removed Ozempic from its drug list, often at the start of a new plan year. The Kaiser Family Foundation's 2024 Employer Health Benefits Survey found formulary changes are one of the most common reasons specialty drug coverage shifts mid-treatment.
  • Prior authorization denied or expired: Many plans require annual reauthorization. If your doctor didn't resubmit in time, coverage can lapse automatically.
  • Indication mismatch: Ozempic is FDA-approved only for type 2 diabetes. If your insurer believes it's being used for weight loss, it may deny or rescind coverage — even if blood sugar control is a secondary benefit.
  • Step therapy requirement: Some plans require you to try and fail cheaper medications (such as metformin) before approving a GLP-1.
  • Job or plan change: Switching employers or entering a new plan year can reset your coverage entirely.

What Are Your Immediate Options?

Stopping Ozempic abruptly can cause blood sugar levels to rise rapidly in people with type 2 diabetes. If your last covered dose is approaching, talking to your prescriber first lets you bridge to a savings card, alternative medication, or transition plan instead of an unplanned gap.

Once you know why coverage ended, work through these steps in order:

  1. Call your insurer and ask for the specific denial code. You cannot appeal effectively without the exact reason in writing. Request the Explanation of Benefits (EOB) document.
  2. Ask your prescriber to submit a prior authorization (PA) or resubmit an expired one. Many lapses are administrative and resolved within days.
  3. File a formal appeal. Under the Affordable Care Act, you have the right to an internal appeal and, if that fails, an independent external review. Your insurer must respond within 30 days for non-urgent cases, 72 hours for urgent ones.
  4. Apply for the Novo Nordisk savings card. Eligible commercially insured patients may pay as little as $25 per month. Uninsured patients can also apply for separate assistance through Novo Nordisk's Patient Assistance Program.
  5. Ask your pharmacist about 90-day supply pricing. Some cash-pay pharmacies and discount programs like GoodRx offer lower per-dose costs on larger fills.

For a detailed walkthrough of the appeals process, see How to Appeal an Insurance Denial for Wegovy or Zepbound — the same framework applies to Ozempic denials.

How to Appeal a Denial: Step by Step

A strong appeal letter includes four elements your prescriber's office should provide:

  • Clinical necessity documentation: A1c levels, prior medication history, and any cardiovascular risk factors. The SELECT trial (Lincoff et al., NEJM, 2023) demonstrated a 20% reduction in major cardiovascular events with semaglutide, which can support medical necessity arguments for high-risk patients.
  • Step therapy exemption request: If your state has step therapy protection laws (26 states had them as of 2024), your prescriber can request an exemption if prior drugs were contraindicated or caused adverse effects.
  • Letter of medical necessity: Specifically citing the FDA-approved indication (type 2 diabetes management per Ozempic's prescribing information) strengthens the case.
  • Peer-to-peer review request: Your prescriber can speak directly with the insurer's medical reviewer. This step resolves many denials that survive the initial written appeal.

What Covered Alternatives Exist?

If an appeal fails, ask your prescriber whether a covered alternative makes clinical sense for you. Options vary by plan, but commonly covered GLP-1 or diabetes medications include:

  • Rybelsus (oral semaglutide): The same active ingredient as Ozempic in pill form. Some formularies cover one but not the other.
  • Trulicity (dulaglutide): A weekly GLP-1 injection. The REWIND trial showed cardiovascular benefit in people with type 2 diabetes.
  • Victoza (liraglutide): A daily GLP-1 injection, FDA-approved for type 2 diabetes and cardiovascular risk reduction.
  • Mounjaro (tirzepatide): A dual GIP/GLP-1 agonist approved for type 2 diabetes. Some plans that dropped Ozempic still cover Mounjaro. See our full Mounjaro overview for details.

Timeline: What to Do Week by Week

Timeframe Action Who Does It
Day 1–3 Get denial in writing; call prescriber's office You + prescriber
Day 3–7 Prescriber submits PA or appeal letter with clinical documentation Prescriber's office
Day 7–14 Apply for Novo Nordisk savings card as backup while appeal is pending You
Day 14–30 Insurer responds to internal appeal (ACA-mandated deadline) Insurer
Day 30–45 If denied again, request external independent review You + prescriber
Ongoing Explore formulary alternatives or patient assistance if external review fails You + prescriber

Is Compounded Semaglutide a Viable Backup?

During periods when FDA-listed drug shortages existed, compounding pharmacies legally produced semaglutide. However, the FDA removed semaglutide from its shortage list in 2025, which significantly restricts legal compounding. As of 2025, most compounded semaglutide from 503A pharmacies (traditional compounders) is no longer permitted for routine dispensing under FDA guidance. 503B outsourcing facilities may still have limited pathways. This is a fast-changing area — ask your prescriber for the most current guidance before pursuing this route.

Frequently Asked Questions

Yes, in most cases. Insurers can change formularies mid-year for employer-sponsored plans with proper notice. However, ACA marketplace plans generally cannot remove a drug mid-year if you are actively taking it, and must provide transition supply. Check your plan documents and state insurance laws, which vary.
The list price for Ozempic is approximately $935–$1,000 per month for a 4-pen supply as of 2025. With the Novo Nordisk savings card, eligible commercially insured patients may pay as low as $25/month. Uninsured patients may qualify for Novo Nordisk's Patient Assistance Program, which provides the medication at no cost based on income.
Medicare Part D plans can cover Ozempic for type 2 diabetes, though formulary placement varies by plan. Medicare does not cover Ozempic for weight loss. Coverage policy shifted in 2026 under the Inflation Reduction Act, which brought changes to Part D cost-sharing. Check your specific Part D plan's formulary each year during open enrollment.
No, but it substantially improves appeal odds. A letter of medical necessity is required for most appeals, and peer-to-peer reviews between your prescriber and the insurer's physician reviewer resolve many denials. Medical necessity alone does not override formulary exclusions, but it is essential documentation for the appeals process and external review.
Wegovy contains the same active ingredient (semaglutide) but is FDA-approved specifically for chronic weight management, not type 2 diabetes. Some plans that dropped Ozempic still cover Wegovy for qualifying patients with obesity and weight-related conditions. However, many commercial plans and Medicare still have limited weight-loss drug coverage. Ask your prescriber whether you qualify and check your plan's formulary.
Under ACA rules, insurers must respond to an internal appeal within 30 days for pre-service requests and 60 days for post-service claims. Urgent care appeals must be decided within 72 hours. If the internal appeal is denied, an external independent review typically takes 45 days, though expedited reviews for urgent medical situations must be completed within 72 hours.
Per the Ozempic FDA prescribing information, stopping semaglutide can cause blood glucose to rise — so most patients talk to their prescriber before pausing treatment. Many prescribers can bridge the gap with a savings card or patient assistance program, or temporarily adjust the diabetes management plan while an appeal is pending.

Every insurance situation is different, and the options above involve both medical and financial decisions. Talk to your prescriber before making any changes to your medication, and consider contacting a patient advocate or your state's insurance commissioner if you believe a denial was improper. Your prescriber's office is often the most effective first call — many practices have prior authorization specialists who handle these situations routinely.

Sources
  • Novo Nordisk, Ozempic (semaglutide) U.S. Prescribing Information, FDA, 2023
  • Wilding JPH et al., STEP 1 trial, NEJM, 2021
  • Lincoff AM et al., SELECT trial (semaglutide and cardiovascular outcomes), NEJM, 2023
  • Kaiser Family Foundation, Employer Health Benefits Survey, KFF, 2024
  • Davies M et al., SUSTAIN-6 trial, NEJM, 2016

Keep Reading

Do GLP-1 Medications Reduce Alzheimer's Risk? What New Studies ShowResearch & News · 6 min readNext-Generation GLP-1 Drugs in the Pipeline: What Is Coming After TirzepatideResearch & News · 7 min read

This site provides general information only and does not constitute medical advice. All content is sourced to FDA labeling, NIH publications, or peer-reviewed clinical trials. Always consult your prescriber before making any medication decision.